Focused ultrasound plus newer hormone therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a treatment that uses high-intensity focused ultrasound to target and destroy cancer cells in the prostate, combined with a newer hormone therapy. This approach may help control advanced prostate cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have newly diagnosed prostate cancer that has spread to other parts of the body or is locally advanced and cannot be removed by surgery.
- Your cancer was confirmed by a special PET/CT scan (PSMA PET/CT).
- You have not had any prior treatment for prostate cancer (like surgery, radiation, or hormone therapy).
- Your overall health is good enough that you can do light work or most daily activities.
- You do not have any other active cancer, except for certain non-serious skin cancers or a fully treated early-stage cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a high-intensity focused ultrasound treatment can help people with localized prostate cancer while still avoiding traditional full-dose treatment for some patients. It may be an option for certain intermediate-risk cases where the cancer is confined to the prostate.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This trial studies a focused ultrasound treatment called HIFU for prostate cancer that appears limited to the early stages. It aims to treat cancer within the prostate while avoiding treatment spread to lymph nodes or distant organs.
This trial tests if a focused ultrasound treatment can safely and effectively treat prostate cancer that has come back after radiation therapy. The ultrasound uses sound waves to heat and destroy cancer cells in a specific area of the prostate while sparing healthy tissue.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.